March 2017 Current Affairs
24 MAR
NEWS
23 MAR
NEWS
22 MAR
NEWS
21 MAR
NEWS
20 MAR
NEWS
18 MAR
NEWS

February 2017 Current Affairs
28 FEB
NEWS
27 FEB
NEWS
25 FEB
NEWS
24 FEB
NEWS
23 FEB
NEWS
22 FEB
NEWS

January 2017 Current Affairs
31 JAN
NEWS
30 JAN
NEWS
28 JAN
NEWS
27 JAN
NEWS
25 JAN
NEWS
24 JAN
NEWS

December 2016 Current Affairs
31 DEC
NEWS
30 DEC
NEWS
29 DEC
NEWS
28 DEC
NEWS
27 DEC
NEWS
26 DEC
NEWS

November 2016 Current Affairs
30 NOV
NEWS
29 NOV
NEWS
28 NOV
NEWS
26 NOV
NEWS
25 NOV
NEWS
24 NOV
NEWS

Zydus, Medicines Patent Pool inks agreement for Bristol-Myers Squibb's daclatasvir tablets

Zydus, Medicines Patent Pool inks agreement for Bristol-Myers Squibb's daclatasvir tablets
09 July 2016 Current Affairs: Zydus Cadila, a leading global healthcare firm, on 7 July 2016 inked a non-exclusive, royalty free agreement with the Medicines Patent Pool (MPP). Under the pact they will be manufacturing global pharma major Bristol-Myers Squibb’s daclatasvir tablets used for the treatment of Hepatitis C Virus (HCV).

Bristol-Myers Squibb’s daclatasvir is a novel direct-acting antiviral (DAA) that is proven to help cure multiple genotypes of HCV.

The agreement sub-licences Zydus to produce and sell daclatasvir in 112 low and middle income countries. Between 130 and 150 million people worldwide are estimated to have HCV.

The MPP licence allows generic manufacturers to develop fixed-dose combinations that offer the potential to treat all of the six major genotypes of HCV. Daclatasvir, in combination with other DAAs, for example sofosbuvir, produces high cure rates after 12 weeks of treatment, with recent Phase III studies demonstrating  that  the  regimen  could  cure  up  to  100%  of  HCV  patients  depending  on genotype and stage of liver disease.

Zydus Cadila : Zydus  Cadila  is  an  innovative,  global  pharmaceutical  company  that  discovers,  develops, manufactures and markets a broad range of healthcare therapies. The group launched its own patented NCE –Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

It also launched ‘Exemptia’ the world’s first biosimilar of Adalimumab for the treatment  of  inflammatory  arthritis,  Ulcerative  Colitis  and  Crohn’s  Disease  in  adult  & paediatric  patients.  The group aspires to be a research-based pharmaceutical company by 2020. The group employs over 19000 people worldwide.


March 2017 Current affairs
24 MAR
NEWS
23 MAR
NEWS
22 MAR
NEWS
21 MAR
NEWS
20 MAR
NEWS
18 MAR
NEWS

February 2017 Current affairs
28 FEB
NEWS
27 FEB
NEWS
25 FEB
NEWS
24 FEB
NEWS
23 FEB
NEWS
22 FEB
NEWS




January 2017 Current affairs
31 JAN
NEWS
30 JAN
NEWS
28 JAN
NEWS
27 JAN
NEWS
25 JAN
NEWS
24 JAN
NEWS

December 2016 Current affairs
31 DEC
NEWS
30 DEC
NEWS
29 DEC
NEWS
28 DEC
NEWS
27 DEC
NEWS
26 DEC
NEWS

November 2016 Current affairs
30 NOV
NEWS
29 NOV
NEWS
28 NOV
NEWS
26 NOV
NEWS
25 NOV
NEWS
24 NOV
NEWS



FreshersLive - No.1 Job site in India. Fresherslive Current Affairs 2017 section offers informative quiz questions with answers regarding latest current affairs today for all sorts of competitive exams like UPSC, TNPSC , IFS, IAS, IPS, railway exams (RRB) and banking exams like IPBS PO, IPBS clerk, Federal Bank PO, ICICI, SBI, RBI legal officer & Grade officer posts and much more. Register with us to get latest Current Affairs Updates. Also get latest Current Affairs news and quiz Updates for free alerts daily through E-mail

Get Daily Current Affairs to your Email

You can Unsubscribe us at any time.

Get Daily Current Affairs to your Email

You can Unsubscribe us at any time.